ClinicalTrials.gg
Active, not recruitingNCT07505004POWER2Updated Aug 3, 2026

Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

A Phase 3 interventional study of 40 mg/day vormatrogine for 12 weeks and 30 mg/day vormatrogine for 12 weeks in Focal Epilepsy, sponsored by Praxis Precision Medicines. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Praxis Precision Medicines · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.

Planned enrollment
21st of 86
300 · median 100
Started
2026
with 5 others
Phase 3
31 of 102
3 open now
Primary completion
2027-01
later than 8 of 22 live
Registered
97th of 102
by date

Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 21st largest by planned enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2026, is one of 31 in phase 3, reaches primary completion later than 8 of the 22 other live ones, and was the 97th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Epilepsies, Partial with a site in United States, or all of them as a file.
02

Study summary

A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)

Read the detailed description

PRAX-628-322 (POWER 2) is a Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures.

03

Conditions studied

  • Focal Epilepsy

Browse trials for

Keywords

  • focal epilepsy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of focal onset epilepsy according to the International League Against Epilepsy Classification of Epilepsy (2017).
  • Prior to randomization, past evidence by CT or MRI that has ruled out a progressive cause of epilepsy in the judgement of the investigator and/or in consultation with the medical monitor.
  • Participant must attest to be taking stable doses of 1 or up to 3 acceptable ASMs for at least 4 weeks prior to screening and during screening prior to Day 1.
  • Has at least 4 countable focal onset seizures during the 4 weeks of Observation Period immediately prior to randomization with no more than 21 days seizure free during this period.
  • Seizure diary must be completed for ≥80% days in the Observation Period.

Exclusion criteria

Exclusion Criteria:

  • Participant has had any of the following within the 12-month period preceding trial entry:

    1. evidence of experiencing pseudo or psychogenic seizures
    2. cluster seizures where the individual seizures cannot be counted
    3. an episode of convulsive status epilepticus requiring hospitalization and intubation
    4. seizures secondary to illicit drug or alcohol use
  • Seizures secondary to ongoing infection, neoplasia, demyelinating disease, progressive degenerative disease, metabolic illness deemed progressive, progressive structural lesion or encephalopathy.
  • Previously documented EEG which shows any pattern not consistent with focal etiology of seizures.
  • Planned epilepsy surgery during the course of the clinical trial.
  • History of any of the following:

    1. neurosurgery for seizures \<1 year prior to enrollment
    2. radiosurgery \<2 years prior to enrollment
    3. neurostimulator placed \<1 year prior to Screening
    4. neurostimulator placed >1 year prior to Screening but settings have not been stable for at least 2 months prior to Screening
  • Active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt, as confirmed by C-SSRS.
  • Has any significant ongoing disease, disorder, laboratory abnormalities, alcohol or drug abuse or dependence, environmental factor, or ongoing or recent history of any psychiatric, medical, or surgical condition.
  • Participants with a history of , myeloproliferative or lymphoproliferative disorders within the past 3 years are excluded.
  • History or presence of uncontrolled cardiac diseases including conduction and structural abnormalities.
  • Total value >1.5×; an or AST value >3×ULN.
  • History of or active infection or positive screening result for: HIV 1 or 2 antibodies. Evidence of active or infection, as determined by relevant screening assessments.
  • Has received any other experimental or drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene or cell therapy.
  • Vigabatrin: Use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin.
  • Felbamate: If used as a concomitant ASM, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to Screening. If a patient received felbamate in the past, it must have been discontinued 2 months prior to screening.
  • Significant allergic reaction to an ASM(s), including dermatological (e.g. Stevens-Johnson syndrome), hematological, or organ toxicity reactions. Severe reactions do not include simple maculopapular eruption and allergic rhinitis.
  • Is pregnant or breastfeeding at the time of Screening or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or prior to end of study visit.
  • Previous exposure to vormatrigine or known to any component used in the vormatrigine formulation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    40 mg/day vormatrogine for 12 weeks

    Participants who meet all eligibility criteria will be randomized at Visit 1 (Day 1) to receive 40 mg of vormatrogine

    Drug: 40 mg/day vormatrogine for 12 weeks

  • Experimental
    30 mg/day vormatrogine for 12 weeks

    Participants who meet all eligibility criteria will be randomized at Visit 1 (Day 1) to receive 30 mg of vormatrogine

    Drug: 30 mg/day vormatrogine for 12 weeks

  • Experimental
    20 mg/day vormatrogine for 12 weeks

    Participants who meet all eligibility criteria will be randomized at Visit 1 (Day 1) to receive 20 mg of vormatrogine

    Drug: 20 mg/day vormatrogine for 12 weeks

  • Placebo comparator
    Placebo per day for 12 weeks

    Participants who meet all eligibility criteria will be randomized at Visit 1 (Day 1) to receive placebo

    Drug: Placebo

Interventions

  • Drug40 mg/day vormatrogine for 12 weeks

    Once daily oral

  • Drug30 mg/day vormatrogine for 12 weeks

    Once daily oral

  • Drug20 mg/day vormatrogine for 12 weeks

    Once daily oral

  • DrugPlacebo

    Once daily oral

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of vormatrigine compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs

    Median percent change in monthly (28 days) focal seizure frequency from the Screening/Observation Period to the Treatment Period for vormatrogine compared to placebo.

    Time frame: 12 weeks

Secondary outcomes

  1. To further evaluate the efficacy of vormatrigine compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs

    Proportion of participants experiencing a ≥50% reduction in monthly (28 days) focal seizure frequency from the Screening/Observation Period to the Treatment Period (Responder Rate) for vormatrogine compared to placebo

    Time frame: 12 weeks

  2. To assess trends over time in efficacy of vormatrogine on focal seizure frequency

    Percent change in monthly focal seizure frequency from the Screening/Observation Period to the Treatment Period for vormatrogine compared with placebo.

    Time frame: 12 weeks

  3. To assess the safety and tolerability of vormatrigine in adults with focal seizures

    Incidence and severity of TEAEs, including discontinuation of study drug due to TEAEs

    Time frame: 12 weeks

  4. To assess the safety and tolerability of vormatrigine in adults with focal seizures

    Change in tympanic temperature in Celsius

    Time frame: 12 weeks

  5. To assess the safety and tolerability of vormatrigine in adults with focal seizures

    Change in heart rate in beats per minute

    Time frame: 12 weeks

  6. To assess the safety and tolerability of vormatrigine in adults with focal seizures

    Change in blood pressure in mm/Hg

    Time frame: 12 weeks

  7. To assess the safety and tolerability of vormatrigine in adults with focal seizures

    Change in respiratory rate in breaths per minute

    Time frame: 12 weeks

  8. To assess the safety and tolerability of vormatrigine in adults with focal seizures

    The principal investigator (PI) or sub investigator will review the laboratory report and document this review. Any clinically significant adverse changes occurring during the clinical trial will be documented as adverse events

    Time frame: 12 weeks

  9. To assess the safety and tolerability of vormatrigine in adults with focal seizures

    Incidence of clinically significant ECG abnormalities

    Time frame: 12 weeks

  10. To assess the safety and tolerability of vormatrigine in adults with focal seizures

    Changes in suicidality, as assessed by Columbia-Suicide Severity Rating Scale

    Time frame: 12 weeks

07

Study locations

7 sites
  • Praxis Research Site
    Miami, Florida 33133, United States
  • Praxis Research Site
    Miami Lakes, Florida 33016, United States
  • Praxis Research Site
    Naples, Florida 34116, United States
  • Praxis Research Site
    Marlboro, New Jersey 07746, United States
  • Praxis Research Site
    Niagara Falls, New York 14304, United States
  • Praxis Research Site
    Raleigh, North Carolina 27607, United States
  • Praxis Research Site
    Houston, Texas 77058, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 1, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Jan 2027
CompletionEst.
May 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07505004
Lead sponsor
Praxis Precision Medicines
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Jan 29, 2026
Primary completion
Jan 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Praxis Precision Medicines
study director · Praxis Precision Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion